Browse drugs

…ions. Crucially, we detail how workforce shortages, inequitable opioid access and financing gaps create predictable disparities for pa…

…he previous decade, WHO supported large trials in South Asia of oral antibiotics and outpatient treatment of ALRI.…

… and persistent immune suppression. Integrating next-generation RAS inhibitors with RT and immune-directed therapies may therefore represent a…

…ntravitreal anti-vascular endothelial growth factor (anti-VEGF) ranibizumab was used, which achieved rapid resolution of hyphaema with resu…

…ltiple deciduous teeth under total intravenous anaesthesia with propofol. Within hours of surgery, he developed diffuse abdominal pain. …

…intrasaccular device can be used alongside products such as the Rebar microcatheter 18 and Navien.2 In Europe, an adequate occlusion rate of 78% at 12…

…farct volume progression (median 2.3 vs 4.7 mL; P=0.045), lower interleukin 6 levels (median 26.4 vs 32.6 pg/mL; P=0.032), higher Th/CTL rati…

…2008 and 31 December 2023, and no prior history of type 2 DM or metformin use.Primary outcome measure New-onset type 2 DM (HbA1c ≥6.5%) i…

…o iCAF specification and immunosuppression in PDAC. Cotargeting IL-17 and ITGA5 synergises with PD-1 blockade, providing a rationale …

…100%) and 96% (95% CI 81% to 100%), respectively.Conclusion The KIT-FISTO was derived and internally validated to predict obstructive AKI…

…nial immune response driving stroke progression. Interleukin-7 (IL-7) is implicated in neuroinflammation but remains understudied in…

…en. 30.2% (157/520) of cases were on dual antiplatelet therapy (DAPT) or therapeutic anticoagulation. Among the 520 Celt ACD closure…